Last updated on July 2015

Observatory of Invasive Procedures and Bleeding in Patients Treated With New Oral Anticoagulants

Brief description of study

The arrival on the market of direct oral factor Xa and factor IIa inhibitors (dabigatran (Pradaxa®), rivaroxaban (Xarelto®), apixaban (Eliquis®) and others soon to come) raises novel questions among clinicians confronted with the emergency management of patients treated with these new drugs. It is likely that these new oral anticoagulants (NOACs) will eventually win a significant market share in the indications secondary prevention of venous thromboembolism and prevention of cardioembolic events in patients with nonvalvular atrial fibrillation, due to their net clinical benefit and their practicality of use compared with vitamin K antagonists (VKAs). However, despite the fact that NOACs reduce the incidence of intracranial bleeding by about half compared with VKAs, the risk remains significant; furthermore, in clinical trials, these drugs had little or no effect on reducing the incidence of major extracranial bleeding. In everyday practice, where the indication could be expanded to unselected populations and due to a potential for misuse, it is likely that the incidence of bleeding complications will be higher than that reported in clinical trials. Indeed, the numerous alerts emanating from regulatory agencies in various countries (US, Australia, etc.) bear witness to this, and should serve as a reminder that these anticoagulants have a real potential for bleeding complications and, in the absence of an antidote, there is no validated management strategy. Furthermore, as these drugs can be prescribed for months or years, patients may eventually be exposed to situations at high hemorrhagic risk, such as emergency surgery or invasive procedures, trauma, etc. Analysis of data from the RE-LY trial (dabigatran versus warfarin in patients with atrial fibrillation) showed that during the two years of follow-up, approximately 25% of the patients underwent an invasive procedure, ranging from pacemaker insertion to major surgery. Thus, a large proportion of patients treated with NOACs are concerned by this issue. In anticipation of a gradually increasing influx of patients in a critical situation (active bleeding or need to rapidly secure hemostasis before an invasive procedure), it is urgent to define the conduct to adopt based on the experience gained from the earliest cases. This is the objective of the French-speaking GIHP-NACO observatory set up by the GIHP (French Working Group on Perioperative Hemostasis). For the moment, then, the management recommendations derive from expert opinions based on pharmacokinetic data and on the partial correction of NOAC-induced hypocoagulability by various nonspecific procoagulants (non-activated or activated prothrombin complex concentrates, recombinant factor VIIa). These procoagulants are currently used in an empirical manner to control bleeding, with as many successes as failures reported in the literature, and their benefit-risk ratio in these patients is therefore uncertain.

Detailed Study Description

The management of critical situations is difficult for several reasons: - First, there is significant intra- and inter-individual variability in the pharmacokinetics of NOACs, which is further heightened in the critical setting by drug interactions with other agents that interfere with P-GP (P-GLYCOPROTEIN)and cytochrome P4503A4 in patients who are often elderly and multi medicated, and by rapid variations in renal function, which is essential for elimination of NOACs. - Second, biological guidance is weak: there is no clearcut therapeutic range nor any validated hemostatic safety cutoff, as is the case with the INR (International Normalized Ratio) for VKAs. Conventional coagulation tests (PT/aPTT) are poorly standardized and difficult to interpret. Assays to measure the serum concentrations of these drugs are not widespread outside of a few teaching hospitals. - Third, there is a lack of clinical experience. Analyses of critical situations that occurred during clinical trials were done after the fact and the data collected are heterogeneous and incomplete. Clinical cases reported in the literature are rarely well documented. The objective of the observatory is to rapidly acquire documented and thorough feedback on clinical experience with these new drugs that will be able to confer a higher level of evidence to the management recommendations for treated patients.

Clinical Study Identifier: NCT02185027

Find a site near you

Start Over

CH Alpes leman

Contamine-sur-Arve, France
  Connect »

CHU Montpellier

Montpellier, France
  Connect »

CHU Marseille

Marseille, France
  Connect »

CHU Bordeaux

Bordeaux, France
  Connect »

CHU Dijon

Dijon, France
  Connect »

CH Castres

Castres, France
  Connect »

CHR Annecy

Annecy, France
  Connect »

CH Chamb ry

Chambery, France
  Connect »

CHU Besan on

Besançon, France
  Connect »

CHU Toulouse

Toulouse, France
  Connect »


Paris, France
  Connect »

CH Voiron

Voiron, France
  Connect »

CHU Rennes

Rennes, France
  Connect »

CHU Brugmann

Brussels, Belgium
  Connect »

CH Gap

GAP, France
  Connect »

CH Agen

Agen, France
  Connect »

CHU Clermont-Ferrand

Clermont-ferrand, France
  Connect »

CHU Nancy

Nancy, France
  Connect »

CHU Nantes

Nantes, France
  Connect »

CHU Nimes

Nimes, France
  Connect »

Recruitment Status: Open

Brief Description Eligibility Contact Research Team

Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.